Tirzepatide: dual GIP/GLP-1 receptor agonist research overview

Tirzepatide is a synthetic dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist developed by Eli Lilly and Company, approved by the FDA in May 2022 under the trade name Mounjaro for type 2 diabetes and in November 2023 as Zepbound for chronic weight management. As the first approved agent to simultaneously engage both incretin receptors — earning it the informal designation 'twincretin' — tirzepatide has attracted significant scientific interest for the synergistic metabolic effects produced by combined GIP and GLP-1 receptor activation. The compound demonstrated effect sizes in phase 3 obesity trials that exceeded previously observed benchmarks for a single-agent injectable in this class, making it a central focus of ongoing metabolic research.

What is tirzepatide?

Tirzepatide is a 39-amino acid synthetic polypeptide with a molecular weight of 4,813.48 Da. Its backbone is derived from the sequence of endogenous GIP rather than GLP-1, a structural distinction from all previously marketed GLP-1 agonists. The compound is acylated at a lysine residue with a C20 fatty diacid chain attached via a gamma-glutamic acid/mini-PEG linker, enabling reversible binding to serum albumin and achieving a plasma half-life of approximately 5.4 days — sufficient for once-weekly subcutaneous dosing. Tirzepatide binds the GIP receptor with affinity essentially equal to that of native GIP, while its affinity for the GLP-1 receptor is approximately five-fold lower than native GLP-1, a pharmacological asymmetry that differentiates it from peptides designed as balanced dual agonists.

Tirzepatide was developed by Eli Lilly under the development code LY3298176. FDA approval for type 2 diabetes (Mounjaro) was granted in May 2022 based on the SURPASS phase 3 program. FDA approval for chronic weight management (Zepbound) followed in November 2023 based on the SURMOUNT phase 3 program. Regulatory approvals have also been granted in the European Union and other jurisdictions. In research contexts outside approved clinical settings, tirzepatide is classified as a research-use compound.

Mechanism of action

Tirzepatide achieves its biological effects by co-activating two distinct class B G protein-coupled receptors: the GIP receptor (GIPR) and the GLP-1 receptor (GLP-1R). Both receptors signal primarily through Gs-coupled adenylate cyclase pathways, raising intracellular cyclic AMP. At pancreatic beta cells, GLP-1R activation potentiates glucose-dependent insulin secretion — the well-established incretin mechanism shared with GLP-1 agonists. GIP receptor activation provides an additive insulinotropic effect; importantly, GIP also stimulates insulin secretion in a glucose-dependent fashion, maintaining a favorable hypoglycemia profile.

The combination of GIP and GLP-1 receptor co-activation produces a synergistic insulin response that exceeds what either hormone produces alone when given at matched doses, a phenomenon documented in human clamp studies. Beyond the pancreas, tirzepatide engages GLP-1 receptors in the hypothalamus and brainstem to suppress appetite and reduce energy intake, similar to semaglutide. GIP receptor activation may contribute additional central satiety signaling; GIP receptors are expressed in the hypothalamus and limbic regions. Tirzepatide also modestly inhibits glucagon secretion in hyperglycemic states and delays gastric emptying, though published data suggest the delay in gastric emptying may be attenuated relative to GLP-1 monoagonists at clinically evaluated doses, potentially contributing to better gastrointestinal tolerability profiles observed in some trial comparisons (see citations).

GIP has historically been described as an incretin hormone with additional roles in lipid metabolism, adipose tissue function, and bone density. Some preclinical evidence suggests GIP receptor signaling modulates adipose energy storage and mobilization in ways that may complement GLP-1-mediated appetite suppression, though the precise contribution of each receptor pathway to the observed cardiometabolic effects of tirzepatide in humans is an active area of investigation (see citations).

What the research shows

The SURPASS clinical trial program (SURPASS 1–5) evaluated tirzepatide in adults with type 2 diabetes across a range of comparator arms, including placebo, semaglutide 1 mg, insulin degludec, and insulin glargine. SURPASS-2 (NCT03987919), published by Frías et al. in the New England Journal of Medicine in 2021 (PMID 34170647), enrolled 1,879 adults with type 2 diabetes inadequately controlled on metformin and compared tirzepatide 5 mg, 10 mg, and 15 mg to semaglutide 1 mg. At 40 weeks, all three tirzepatide doses reduced HbA1c and body weight significantly compared to semaglutide 1 mg, with the 15 mg dose achieving a mean HbA1c reduction of 2.46% and body weight reduction of 5.86 kg versus semaglutide 1 mg (see citations).

The SURMOUNT program evaluated tirzepatide for chronic weight management in adults without type 2 diabetes. SURMOUNT-1 (NCT04184622), published by Jastreboff et al. in the New England Journal of Medicine in 2022 (PMID 35658024), enrolled 2,539 adults with obesity or overweight without diabetes and evaluated tirzepatide at 5, 10, and 15 mg weekly over 72 weeks. The 15 mg arm achieved a mean weight reduction of approximately 20.9% from baseline, versus 3.1% with placebo. The proportion of participants achieving 20% or more weight reduction was 57% in the 15 mg group versus 3% with placebo (see citations). These effect sizes at the 15 mg dose were the largest reported for a once-weekly injectable agent at the time of publication.

Additional SURMOUNT trials (SURMOUNT-2, -3, -4) evaluated tirzepatide in adults with type 2 diabetes and obesity, in combination with intensive lifestyle intervention, and in a maintenance/withdrawal design respectively. SURMOUNT-4 demonstrated that participants who discontinued tirzepatide after 36 weeks regained a mean of approximately 14% body weight over the subsequent 52 weeks, emphasizing the sustained nature of the biological targets engaged. The SURPASS-CVOT trial (NCT04255433), an ongoing cardiovascular outcomes trial, is evaluating tirzepatide versus dulaglutide in high-risk type 2 diabetes patients for hard cardiovascular endpoints; results are anticipated in the coming years.

Pharmacokinetics

Tirzepatide has an elimination half-life of approximately 5.4 days, enabling once-weekly subcutaneous dosing with achievement of steady-state plasma concentrations after approximately 4 weeks. Following subcutaneous injection, time to maximum plasma concentration (Tmax) ranges from 8 to 72 hours. Mean absolute subcutaneous bioavailability is approximately 80%. Population pharmacokinetic modeling published in 2024 (PMC10962491) confirmed dose-proportional exposure across the approved dose range of 2.5 mg to 15 mg in the studied populations (see citations).

Like semaglutide, tirzepatide's extended half-life is achieved through albumin binding via its fatty acid acylation, but tirzepatide employs a C20 fatty diacid chain (versus semaglutide's C18 diacid), connected through a longer gamma-glutamic acid/mini-PEG linker. The apparent population mean clearance is approximately 0.061 L/h. Tirzepatide is not a CYP450 substrate; metabolic elimination occurs via proteolytic cleavage of the peptide backbone and beta-oxidation of the fatty acid side chain. Renal or hepatic impairment does not significantly alter exposure based on published pharmacokinetic assessments. The FDA prescribing information for Mounjaro (NDA 215866) and Zepbound (NDA 217806) provide the full pharmacokinetic parameter tables.

Common research dose ranges

Not medical advice. These are ranges reported in research literature, not personalized recommendations. Consult your physician.

Phase 3 clinical literature reports subcutaneous doses of 2.5 mg, 5 mg, 10 mg, and 15 mg once weekly for tirzepatide, with escalation in 2.5 mg steps every 4 weeks. The SURMOUNT-1 trial (Jastreboff et al., PMID 35658024) and SURPASS-2 trial (Frías et al., PMID 34170647) both used this escalation schedule, starting at 2.5 mg weekly for 4 weeks, then escalating to maintenance doses of 5, 10, or 15 mg (see citations). The 2.5 mg starting dose is described in the literature as an initiation dose to manage gastrointestinal tolerability; it is not evaluated as a maintenance dose in published trials.

Literature reports once-weekly subcutaneous dosing, starting at 2.5 mg and escalating in 2.5 mg steps every 4 weeks to maintenance doses of 5, 10, or 15 mg, consistent with the ClinicalTrials.gov registry entry for SURMOUNT-1 (NCT04184622). Researchers should consult published protocols and the FDA prescribing information for approved formulations, as experimental designs outside approved indications require appropriate institutional and regulatory oversight.

Storage and handling

Lyophilized tirzepatide peptide is stored at −20 °C in a sealed, desiccant-protected vial. Once reconstituted, solutions should be kept at 2–8 °C and used within 28 days. Reconstituted solutions should not be frozen. Exposure to direct light, heat, and repeated freeze-thaw cycles should be avoided. These parameters align with general lyophilized peptide stability guidance and with the storage requirements described in the FDA-approved prescribing information for Mounjaro and Zepbound pre-filled pens, which specify refrigeration (36–46 °F / 2–8 °C) prior to first use.

What tirzepatide is NOT

Tirzepatide is frequently conflated with semaglutide and retatrutide in popular discussion, but these are structurally and pharmacologically distinct compounds. Tirzepatide is not semaglutide: semaglutide is a GLP-1 monoagonist with a 31-amino acid backbone derived from GLP-1, whereas tirzepatide is a dual agonist with a GIP-derived 39-amino acid backbone. Tirzepatide is not retatrutide: retatrutide adds a third receptor — the glucagon receptor — to the dual GIP/GLP-1 pharmacology of tirzepatide, making it a triple agonist; it is a structurally distinct compound with a different molecular weight (4,731.33 Da) currently in phase 3 trials. Tirzepatide is not mazdutide or survodutide, which are GLP-1/glucagon dual agonists with entirely different receptor profiles. Researchers should verify molecular weight (4,813.48 Da), sequence length (39 amino acids), and COA documentation when sourcing tirzepatide, as the research market uses numerous vendor-assigned trade names for this compound.

References

The citations below represent the primary peer-reviewed and regulatory sources underlying claims in this article. Readers seeking primary data are directed to SURPASS-2 (Frías et al., 2021, PMID 34170647), SURMOUNT-1 (Jastreboff et al., 2022, PMID 35658024), the FDA prescribing information for Mounjaro (NDA 215866) and Zepbound (NDA 217806), the ClinicalTrials.gov registry for NCT04184622 (SURMOUNT-1), and the published population pharmacokinetic analysis (PMC10962491). The FDA clinical pharmacology review for NDA 215866 is publicly available and contains the most detailed absorption, distribution, metabolism, and excretion data.